Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review

Austin H. Nguyen; Sheila B. Bhavsar; Erinn M. Riley; Gabriel C. Caponetti; Devendra Agrawal

doi:10.5114/wo.2016.65600

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2016
vol. 20

Send email

Copy url:

abstract:

Review paper

Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review

Austin H. Nguyen

,

Sheila B. Bhavsar

,

Erinn M. Riley

,

Gabriel C. Caponetti

,

Devendra K. Agrawal

Contemp Oncol (Pozn) 2016; 20 (6): 425–429

DOI: https://doi.org/10.5114/wo.2016.65600

Online publish date: 2017/01/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Nguyen A, Bhavsar S, Riley E, Caponetti G, Agrawal DK. Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review. Contemporary Oncology/Współczesna Onkologia. 2016;20(6):425-429. doi:10.5114/wo.2016.65600.

APA

Nguyen, A., Bhavsar, S., Riley, E., Caponetti, G.,  & Agrawal, D. K. (2016). Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review. Contemporary Oncology/Współczesna Onkologia, 20(6), 425-429. https://doi.org/10.5114/wo.2016.65600

Chicago

Nguyen, Austin H., Sheila B. Bhavsar, Erinn M. Riley, Gabriel C. Caponetti,  and Devendra K Agrawal. 2016. "Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review". Contemporary Oncology/Współczesna Onkologia 20 (6): 425-429. doi:10.5114/wo.2016.65600.

Harvard

Nguyen, A., Bhavsar, S., Riley, E., Caponetti, G.,  and Agrawal, D. (2016). Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review. Contemporary Oncology/Współczesna Onkologia, 20(6), pp.425-429. https://doi.org/10.5114/wo.2016.65600

MLA

Nguyen, Austin H. et al. "Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review." Contemporary Oncology/Współczesna Onkologia, vol. 20, no. 6, 2016, pp. 425-429. doi:10.5114/wo.2016.65600.

Vancouver

Nguyen A, Bhavsar S, Riley E, Caponetti G, Agrawal D. Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review. Contemporary Oncology/Współczesna Onkologia. 2016;20(6):425-429. doi:10.5114/wo.2016.65600.

PlumX metrics:

High-mobility group box 1 (HMGB1) is a versatile protein with nuclear and extracellular functions. In the extracellular milieu, HMGB1 binds to several receptors, notably the receptor for advanced glycation end-products (RAGE). The expressions of HMGB1 and RAGE have been described in a variety of cancers. However, the clinical values of HMGB1 and RAGE in haematological malignancies have yet to be evaluated. A systematic search through PubMed and the Web of Science for articles discussing the role of HMGB1 and RAGE in haematological malignancies produced 15 articles. Overexpression of HMGB1 was reported to be associated with malignancy and, in certain studies, poor prognosis and tumour aggressiveness. Only one included study investigated the clinical value of RAGE, in which no significant difference was found between expression of RAGE in CLL neoplastic cells and nonmalignant controls. The discussed associations of HMGB1 and RAGE with clinicopathological characteristics of patients with haematological malignancies warrants further investigation into the prognostic and diagnostic value of both of these molecules.

keywords:

Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review

Austin H. Nguyen , Sheila B. Bhavsar , Erinn M. Riley , Gabriel C. Caponetti , Devendra K. Agrawal

HMGB1, RAGE, hematological malignancies, leukemia, lymphoma

Austin H. Nguyen

,

Sheila B. Bhavsar

,

Erinn M. Riley

,

Gabriel C. Caponetti

,

Devendra K. Agrawal